PDA is fueled by mutations in four primary drivers; activating mutations of KRAS are accompanied by mutations or silencing of SMAD4, TP53, and CDKN2A that encodes the cyclin dependent kinase (CDK) inhibitor p16INK4A [2]. Here, KRAS is linked to Patent ductus arteriosus.